PriceTargets.com logo

NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.27
  • Forecasted Upside: 110.68 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$13.42 As of 04/20/2021 01:00 AM ET
▼ -5.96 (-30.75%)
1 month | 3 months | 12 months
Get New Syndax Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNDX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$28.27
▲ +110.68% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Syndax Pharmaceuticals in the last 3 months. The average price target is $28.27, with a high forecast of $32.00 and a low forecast of $15.00. The average price target represents a 110.68% upside from the last price of $13.42.
Buy
The current consensus among 11 investment analysts is to buy stock in Syndax Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/21/2021B. RileyReiterated RatingBuyLow
i
Rating by J. Walsh at B. Riley
4/21/2021Robert W. BairdLower Price TargetOutperform$39.00 ➝ $30.00Low
i
2/18/2021B. RileyInitiated CoverageBuy$30.00High
i
Rating by J. Walsh at B. Riley
12/8/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price TargetBuy$23.00 ➝ $31.00High
i
12/8/2020Smith Barney CitigroupBoost Price TargetBuy$23.00 ➝ $31.00Low
i
12/7/2020Morgan StanleyBoost Price TargetEqual Weight$17.00 ➝ $25.00Medium
i
12/7/2020BTIG ResearchBoost Price TargetBuy$26.00 ➝ $32.00Medium
i
12/7/2020BarclaysBoost Price TargetOverweight$29.00 ➝ $31.00High
i
12/2/2020Stifel NicolausInitiated CoverageBuy$32.00High
i
11/19/2020BarclaysBoost Price TargetOverweight$23.00 ➝ $29.00Low
i
11/4/2020Morgan StanleyBoost Price TargetEqual Weight$16.00 ➝ $17.00High
i
5/29/2020Morgan StanleyLower Price TargetEqual Weight$22.00 ➝ $16.00Low
i
5/25/2020NomuraReiterated RatingBuy$31.00Low
i
5/22/2020HC WainwrightDowngradeBuy ➝ Neutral$25.00 ➝ $15.00High
i
Rating by Edward White at HC Wainwright
5/22/2020BarclaysLower Price TargetOverweight$25.00 ➝ $23.00High
i
5/22/2020CitigroupUpgradeNeutral ➝ Buy$26.00 ➝ $23.00High
i
Rating by Joel Beatty at Citigroup Inc.
5/21/2020Morgan StanleyBoost Price TargetEqual Weight$10.00 ➝ $22.00Low
i
5/18/2020CitigroupDowngradeBuy ➝ Neutral$26.00Low
i
5/11/2020HC WainwrightBoost Price TargetBuy$19.00 ➝ $25.00Medium
i
Rating by Edward White at HC Wainwright
5/8/2020NomuraBoost Price Target$16.00 ➝ $31.00High
i
4/30/2020NomuraReiterated RatingBuy$16.00High
i
4/28/2020HC WainwrightBoost Price TargetBuy$18.00 ➝ $19.00High
i
Rating by Edward White at HC Wainwright
4/28/2020Robert W. BairdBoost Price TargetOutperform$27.00 ➝ $33.00High
i
4/21/2020HC WainwrightReiterated RatingBuy$18.00Low
i
Rating by Edward White at HC Wainwright
3/26/2020Nomura SecuritiesReiterated RatingBuy$16.00Medium
i
3/12/2020CitigroupBoost Price Target$12.00 ➝ $18.00High
i
3/11/2020Morgan StanleyBoost Price TargetEqual Weight$8.00 ➝ $10.00Medium
i
3/4/2020HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Edward White at HC Wainwright
3/4/2020Robert W. BairdBoost Price TargetOutperform$20.00 ➝ $27.00High
i
3/4/2020BarclaysInitiated CoverageOverweight$15.00High
i
2/3/2020HC WainwrightReiterated RatingBuy$17.00Low
i
Rating by Edward White at HC Wainwright
1/13/2020HC WainwrightReiterated RatingBuy$15.00 ➝ $17.00High
i
Rating by Edward White at HC Wainwright
12/10/2019HC WainwrightReiterated RatingBuy$15.00Low
i
Rating by E. White at HC Wainwright
11/8/2019CowenReiterated RatingBuyLow
i
10/9/2019B. RileySet Price TargetBuy$14.00Low
i
Rating by Harshita Polishetty at B. Riley
8/11/2019Nomura SecuritiesReiterated RatingBuy$16.00Low
i
8/8/2019CowenReiterated RatingBuyHigh
i
7/16/2019HC WainwrightReiterated RatingBuyLow
i
Rating by E. White at HC Wainwright
3/8/2019Morgan StanleySet Price TargetHold$5.00Medium
i
Rating by David Lebovitz at Morgan Stanley
3/8/2019B. RileySet Price TargetBuy$26.00Medium
i
Rating by Harshita Polishetty at B. Riley
3/8/2019Nomura SecuritiesBoost Price TargetBuy$16.00High
i
3/8/2019BTIG ResearchLower Price TargetBuy$19.00Medium
i
3/8/2019HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $16.00High
i
1/8/2019B. RileyInitiated CoverageBuy$40.00Medium
i
1/4/2019Robert W. BairdInitiated CoverageOutperform ➝ OutperformHigh
i
12/18/2018Nomura SecuritiesLower Price TargetBuy$22.00 ➝ $12.00Low
i
10/29/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$6.00High
i
Rating by David Lebovitz at Morgan Stanley
10/26/2018HC WainwrightLower Price TargetBuy$23.00High
i
Rating by E. White at HC Wainwright
10/11/2018CitigroupLower Price TargetBuy$15.00 ➝ $12.00Medium
i
7/12/2018HC WainwrightInitiated CoverageBuy$30.00High
i
Rating by E. White at HC Wainwright
3/14/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$25.00 ➝ $24.00High
i
1/18/2018B. RileyReiterated RatingBuy$40.00High
i
Rating by M. Kumar at B. Riley
1/5/2018B. RileyInitiated CoverageBuy ➝ Buy$40.00High
i
Rating by M. Kumar at B. Riley
8/14/2017Nomura InstinetReiterated RatingBuy$27.00 ➝ $22.00Low
i
8/11/2017CitigroupSet Price TargetBuy$24.00 ➝ $20.00Medium
i
Rating by Joel Beatty at Citigroup Inc.
8/11/2017Nomura SecuritiesLower Price TargetBuy$27.00 ➝ $22.00Medium
i
8/11/2017OppenheimerBoost Price TargetOutperform$29.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/10/2017Morgan StanleyReiterated RatingOverweight$24.00 ➝ $25.00Low
i
5/19/2017CitigroupSet Price TargetBuy$24.00Low
i
5/19/2017CowenReiterated RatingOutperformLow
i
5/18/2017OppenheimerSet Price TargetBuy$25.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
5/9/2017CowenReiterated RatingBuyHigh
i
5/8/2017OppenheimerSet Price TargetBuy$25.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/24/2017CowenInitiated CoverageOutperformLow
i
3/22/2017OppenheimerReiterated RatingBuyLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/16/2017(FBRC)Initiated CoverageOutperform ➝ Outperform$27.00High
i
Rating by E. White at (FBRC)
3/4/2017OppenheimerSet Price TargetBuy$25.00N/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$27.00N/A
i
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
i
1/26/2017OppenheimerSet Price TargetBuy$24.00 ➝ $25.00N/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
12/30/2016BTIG ResearchInitiated CoverageBuy$25.00N/A
i
11/9/2016JMP SecuritiesReiterated RatingBuyN/A
i
10/7/2016GuggenheimInitiated CoverageBuy$29.00N/A
i
5/17/2016OppenheimerReiterated RatingBuy$24.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
(Data available from 4/21/2016 forward)
Syndax Pharmaceuticals logo
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $13.42
$13.15
$17.66

50 Day Range

MA: $22.85
$19.38
$25.18

52 Week Range

Now: $13.42
$10.20
$27.85

Volume

8,129,639 shs

Average Volume

768,508 shs

Market Capitalization

$647.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Syndax Pharmaceuticals?

The following Wall Street research analysts have issued reports on Syndax Pharmaceuticals in the last year: B. Riley, Barclays PLC, BTIG Research, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Morgan Stanley, Nomura, Robert W. Baird, Smith Barney Citigroup, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for SNDX.

What is the current price target for Syndax Pharmaceuticals?

11 Wall Street analysts have set twelve-month price targets for Syndax Pharmaceuticals in the last year. Their average twelve-month price target is $28.55, suggesting a possible upside of 112.7%. Robert W. Baird has the highest price target set, predicting SNDX will reach $33.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $15.00 for Syndax Pharmaceuticals in the next year.
View the latest price targets for SNDX.

What is the current consensus analyst rating for Syndax Pharmaceuticals?

Syndax Pharmaceuticals currently has 2 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNDX will outperform the market and that investors should add to their positions of Syndax Pharmaceuticals.
View the latest ratings for SNDX.

What other companies compete with Syndax Pharmaceuticals?

Other companies that are similar to Syndax Pharmaceuticals include Amicus Therapeutics, Global Blood Therapeutics, Intra-Cellular Therapies, Ligand Pharmaceuticals, Xencor, Dicerna Pharmaceuticals, Arcus Biosciences, Cryoport, Prestige Consumer Healthcare, ALX Oncology, Zentalis Pharmaceuticals, CytoDyn, Madrigal Pharmaceuticals, MacroGenics and NGM Biopharmaceuticals.

How do I contact Syndax Pharmaceuticals' investor relations team?

Syndax Pharmaceuticals' physical mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company's listed phone number is 781-419-1400 and its investor relations email address is [email protected] The official website for Syndax Pharmaceuticals is www.syndax.com.